Antisense therapy: Difference between revisions
No edit summary |
m added ALS to the list of diseases for which antisense therapies are being researched |
||
| Line 4: | Line 4: | ||
This synthesized nucleic acid is termed an "anti-sense" [[oligonucleotide]] because its [[Base pair|base]] sequence is complementary to the gene's messenger RNA (mRNA), which is called the "sense" sequence (so that a sense segment of mRNA " 5'-AAGGUC-3' " would be blocked by the anti-sense mRNA segment " 3'-UUCCAG-5' "). |
This synthesized nucleic acid is termed an "anti-sense" [[oligonucleotide]] because its [[Base pair|base]] sequence is complementary to the gene's messenger RNA (mRNA), which is called the "sense" sequence (so that a sense segment of mRNA " 5'-AAGGUC-3' " would be blocked by the anti-sense mRNA segment " 3'-UUCCAG-5' "). |
||
Antisense drugs are being researched to treat [[lung cancer]], [[diabetes]] and diseases such as [[asthma]] and [[arthritis]] with an [[inflammatory]] component. Most potential therapies have not yet produced significant clinical results, though one antisense drug, [[fomivirsen]] (marketed as Vitravene), has been approved by the US [[Food and Drug Administration]] (FDA) as a treatment for [[cytomegalovirus retinitis]]. |
Antisense drugs are being researched to treat [[lung cancer]], [[diabetes]], [[Amyotrophic lateral sclerosis|ALS]] and diseases such as [[asthma]] and [[arthritis]] with an [[inflammatory]] component. Most potential therapies have not yet produced significant clinical results, though one antisense drug, [[fomivirsen]] (marketed as Vitravene), has been approved by the US [[Food and Drug Administration]] (FDA) as a treatment for [[cytomegalovirus retinitis]]. |
||
In early [[2006]], scientists studying the [[Ebola]] virus at [[USAMRIID]] announced a 75% recovery rate after infecting four [[rhesus monkey]]s and then treating them with antisense drugs (the usual [[mortality rate]] for monkeys infected with Ebola is 100%).<ref> http://www.usamriid.army.mil/press%20releases/warfield_press_release.pdf</ref> |
In early [[2006]], scientists studying the [[Ebola]] virus at [[USAMRIID]] announced a 75% recovery rate after infecting four [[rhesus monkey]]s and then treating them with antisense drugs (the usual [[mortality rate]] for monkeys infected with Ebola is 100%).<ref> http://www.usamriid.army.mil/press%20releases/warfield_press_release.pdf</ref> |
||
Revision as of 00:12, 16 May 2007
Antisense therapy is a form of treatment for genetic disorders or infections. When the genetic sequence of a particular gene is known to be causative of a particular disease, it is possible to synthesize a strand of nucleic acid (DNA, RNA or a chemical analogue) that will bind to the messenger RNA (mRNA) produced by that gene and inactivate it, effectively turning that gene "off". This is because mRNA has to be single stranded for it to be translated.
This synthesized nucleic acid is termed an "anti-sense" oligonucleotide because its base sequence is complementary to the gene's messenger RNA (mRNA), which is called the "sense" sequence (so that a sense segment of mRNA " 5'-AAGGUC-3' " would be blocked by the anti-sense mRNA segment " 3'-UUCCAG-5' ").
Antisense drugs are being researched to treat lung cancer, diabetes, ALS and diseases such as asthma and arthritis with an inflammatory component. Most potential therapies have not yet produced significant clinical results, though one antisense drug, fomivirsen (marketed as Vitravene), has been approved by the US Food and Drug Administration (FDA) as a treatment for cytomegalovirus retinitis.
In early 2006, scientists studying the Ebola virus at USAMRIID announced a 75% recovery rate after infecting four rhesus monkeys and then treating them with antisense drugs (the usual mortality rate for monkeys infected with Ebola is 100%).[1]
References
See also
External links
- Vitravene Injection Information, from RXlist.com